Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs - GBI Research Reports

Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs

Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs - GBI Research Reports
Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs
Published Dec 01, 2010
153 pages — Published Dec 01, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research's new report, 'Diabetes Market to 2016 - Biguanides and Insulin Analogs to be the Largest Selling Anti-Diabetic Drugs', provides in-depth analysis of unmet needs, drivers and barriers that impact the global diabetes therapeutics market.. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:
- Annualized market data for the diabetes therapeutics market from 2001 to 2009, forecast forward to 2016.
- Market characterization of the diabetes therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development. .
- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global diabetes therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

  
Source:
Document ID
GBIHC046MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents37
1.1 List of Tables62
1.2 List of Figures82
Global Diabetes Market: Introduction101
2.1 GBI Research Report Guidance101
Global Diabetes Market: Market Overview1112
3.1 Introduction111
3.2 Unmet Needs111
3.2.1 Heart Risks Associated with some of the Oral Anti-diabetic Drugs 111
Carcinogenic Effects Associated With Insulin Analogs 121
3.2.3 Poor Patient Compliance121
3.3 Revenue122
3.4 Annual Cost of Therapy141
3.5 Treatment Usage Patterns152
3.5.1 Diseased Population171
3.5.2 Treatment Seeking Population181
3.5.3 Diagnosed Population191
3.5.4 Prescription Population 201
3.6 Drivers and Restraints of Diabetes Market211
3.6.1 Drivers of Diabetes Market211
3.6.1.1 First-in-class Drugs in the pipeline 211
3.6.1.2 Increase in Prescription of Peptide Analogs211
3.6.1.3 Sedentary Lifestyles and Obesity to increase Diabetes Prevalence211
3.6.1.4 Increase in Prevalence and Treatment Seeking 211
3.6.2 Restraints of Diabetes Market211
3.6.2.1 Side Effects Affecting Prescription Sales of Diabetes Drugs211
3.6.2.2 Patent Expiries of Drugs such as Actos, Starlix and Avandia are Expected to Restrain the Growth of the Global Diabetes Therapeutics Market221
4 Global Diabetes Market: Geographical Landscape2325
4.1 The US251
Revenue252
4.1.2 Annual Cost of Therapy271
4.1.3 Treatment Usage Patterns281
4.1.3.1 Diseased Population291
4.1.3.2 Treatment Seeking Population301
4.1.3.3 Diagnosis Population311
4.1.3.4 Prescription Population321
4.2 Top Five EU Countries331
Revenue332
4.2.2 Annual Cost of Therapy 351
4.2.3 Treatment Usage Patterns361
4.2.3.1 Diseased Population371
4.2.3.2 Treatment Seeking Population381
4.2.3.3 Diagnosis Population391
4.2.3.4 Prescription Population401
4.3 Japan411
Revenue411
4.3.2 Annual Cost Therapy421
4.3.3 Treatment Usage Patterns431
4.3.3.1 Diseased Population441
4.3.3.2 Treatment Seeking Population451
4.3.3.3 Diagnosis Population461
4.3.3.4 Prescription Population471
5 Global Diabetes Market: Therapeutic Landscape 4829
5.1 Type 1 Diabetes Market481
5.1.1 Introduction481
5.1.2 Symptoms481
5.1.3 Treatment 482
5.1.4 Unmet need 501
5.1.5 Revenue511
Annual Cost of therapy522
5.1.7 Treatment Usage Patterns542
5.1.7.1 Diseased Population561
5.1.7.2 Treatment Seeking Population571
5.1.7.3 Diagnosis Population581
5.1.7.4 Prescription Population591
5.1.8 Drivers and Restraints for the Type 1 Diabetes Market 601
5.1.8.1 Drivers for the Type 1 Diabetes Market 601
5.1.8.2 Restraints for the Type 1 Diabetes Market 611
5.2 Type 2 diabetes Therapeutics Market611
5.2.1 Introduction611
5.2.2 Symptoms611
5.2.3 Treatment621
5.2.4 Unmet need621
5.2.5 Revenue631
5.2.6 Annual Cost of therapy642
5.2.7 Treatment Usage Patterns662
5.2.7.1 Diseased Population681
5.2.7.2 Treatment Seeking Population691
5.2.7.3 Diagnosis Population701
5.2.7.4 Prescription Population711
5.2.8 Drivers and Restraints for the Type 2 Diabetes Market721
5.2.8.1 Drivers for Type 2 Diabetes Market 721
5.2.8.2 Restraints for Type 2 Diabetes Market 722
5.3 Revenues by Class of Drugs of Type 2 Diabetes743
6 Global Diabetes Market: Pipeline Analysis7729
Introduction772
6.1.1 Research and Development Pipeline Type 1 Diabetes794
6.1.2 Research and Development Pipeline Type 2 Diabetes8311
6.2 Innovations in Diabetes Treatment941
6.2.1 Insulin in Pills (Oral Delivery)941
6.2.2 Promising Treatments for Diabetic Retinopathy941
6.2.3 Biomarkers in Diabetes941
6.2.4 Combination Drugs are an Important Part of the Diabetes Therapeutics Pipeline941
6.3 Drug Delivery in Diabetes951
6.3.1 Factors Determining Preference for Drug Delivery951
6.3.2 Desirable Drug Delivery Methods for Diabetes are Currently Unavailable 951
6.3.3 Innovation in Drug Delivery Systems961
6.3.3.1 Transdermal Passport System961
6.3.3.2 Encapsulation System s U-Strip Insulin System961
6.3.3.3 Technosphere/Insulin 961
6.4 Profiles of Promising Drugs in the Diabetes Market971
6.4.1 rhGAD65 (Diamyd) 971
6.4.2 DiaPep277 971
6.4.3 Otelixizumab981
6.4.4 Oral-lyn 991
6.4.5 BMS-512148 (dapagliflozin) 1001
6.4.6 Victoza (liraglutide)1012
6.4.7 D-Tagatose 1031
6.4.8 JNJ-28431754 (canagliflozin) 1031
6.4.9 MB07803 1042
7 Global Diabetes Market: Competitive Landscape10635
7.1 Diabetes Market Overview1061
7.1.1 Human Insulin Products and Oral Anti-diabetic Drugs Like Actos Group (Actos and Actoplus met) and Lantus Have Led Market Growth 1061
7.2 Market Share Analysis: Diabetes1071
7.3 Competitive Profiling1081
7.3.1 Novo Nordisk1092
7.3.1.1 Product Portfolio1111
7.3.1.2 Marketed Drugs Profile1122
7.3.1.3 Product Pipeline1141
7.3.1.4 SWOT Analysis1151
7.3.2 Sanofi-Aventis1161
7.3.2.1 Product Portfolio1171
7.3.2.2 Marketed Drugs profiles1182
7.3.2.3 Product Pipeline1201
7.3.2.4 SWOT Analysis1201
7.3.3 Takeda1211
7.3.3.1 Product Portfolio1211
7.3.3.2 Marketed Drugs Profiles1221
7.3.3.3 Product Pipeline1231
7.3.3.4 SWOT Analysis1231
7.3.4 Eli Lilly1241
7.3.4.1 Product Portfolio1251
7.3.4.2 Marketed Drug Profiles1262
7.3.4.3 Product Pipeline1281
7.3.4.4 SWOT Analysis1291
7.3.5 GlaxoSmithKline (GSK)1301
7.3.5.1 Product Portfolio1311
7.3.5.2 Marketed Drugs Profiles1312
7.3.5.3 Product Pipeline1331
7.3.5.4 SWOT Analysis1331
7.3.6 Merck &Co Inc1341
7.3.6.1 Product Portfolio1351
7.3.6.2 Marketed Drugs Profle1351
7.3.6.3 Product Pipeline1361
7.3.6.4 SWOT Analysis1361
7.3.7 Amylin Pharmaceuticals1371
7.3.7.1 Product Portfolio1381
7.3.7.2 Marketed Drugs Profiles1381
7.3.7.3 Product Pipeline1391
7.3.7.4 SWOT Analysis1401
8 Global Diabetes Market: M&A Landscape1416
Overview1411
8.1.1 M&A by Geography1421
8.1.2 M&A by Value ($)1431
8.2 R&D Licensing Agreements 1432
8.2.1 Deals by Geography1451
8.2.2 Deals by Value ($)1461
9 Global Diabetes Market: Appendix1477
9.1 Market Definitions1471
9.2 Abbreviations1472
9.3 Research Methodology1494
9.3.1 Coverage1491
9.3.2 Secondary Research1491
9.3.3 Primary Research1491
9.3.4 Forecasts1501
9.3.4.1 Epidemiology-based Forecasting1502
9.3.5 Expert Panel Validation1521
9.4 Contact Us1531
9.5 Disclaimer1531
9.6 Sources1531

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs" Dec 01, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Diabetes-Market-to-2016-Biguanides-and-Insulin-Analogs-will-be-the-Largest-Selling-Anti-Diabetic-Drugs-2115-117>
  
APA:
GBI Research Reports. (2010). Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs Dec 01, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Diabetes-Market-to-2016-Biguanides-and-Insulin-Analogs-will-be-the-Largest-Selling-Anti-Diabetic-Drugs-2115-117>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.